The Experts below are selected from a list of 58278 Experts worldwide ranked by ideXlab platform
Paul J Grippo - One of the best experts on this subject based on the ideXlab platform.
-
animal models challenges and opportunities to determine optimal experimental models of pancreatitis and Pancreatic cancer
Pancreas, 2019Co-Authors: Jami L. Saloman, Kathryn M. Albers, Brian M. Davis, Mouad Edderkaoui, Guido Eibl, Ariel Y Epouhe, Jeremy Y Gedeon, Fred S. Gorelick, Zobeida Cruzmonserrate, Paul J GrippoAbstract:AbstractAt the 2018 PancreasFest meeting, experts participating in basic research met to discuss the plethora of available animal models for studying exocrine Pancreatic Disease. In particular, the discussion focused on the challenges currently facing the field and potential solutions. That meeting
-
Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer
Pancreas, 2019Co-Authors: Jami L. Saloman, Kathryn M. Albers, Zobeida Cruz-monserrate, Brian M. Davis, Mouad Edderkaoui, Guido Eibl, Ariel Y Epouhe, Jeremy Y Gedeon, Fred S. Gorelick, Paul J GrippoAbstract:At the 2018 PancreasFest meeting, experts participating in basic research met to discuss the plethora of available animal models for studying exocrine Pancreatic Disease. In particular, the discussion focused on the challenges currently facing the field and potential solutions. That meeting culminated in this review, which describes the advantages and limitations of both common and infrequently used models of exocrine Pancreatic Disease, namely, pancreatitis and exocrine Pancreatic cancer. The objective is to provide a comprehensive description of the available models but also to provide investigators with guidance in the application of these models to investigate both environmental and genetic contributions to exocrine Pancreatic Disease. The content covers both nongenic and genetically engineered models across multiple species (large and small). Recommendations for choosing the appropriate model as well as how to conduct and present results are provided.
Matthias Lohr - One of the best experts on this subject based on the ideXlab platform.
-
potential for screening for Pancreatic exocrine insufficiency using the fecal elastase 1 test
Digestive Diseases and Sciences, 2017Co-Authors: Enrique J Dominguezmunoz, Philip D Hardt, Markus M Lerch, Matthias LohrAbstract:The early diagnosis of Pancreatic exocrine insufficiency (PEI) is hindered because many of the functional diagnostic techniques used are expensive and require specialized facilities, which prevent their widespread availability. We have reviewed current evidence in order to compare the utility of these functional diagnostic techniques with the fecal elastase-1 (FE-1) test in the following three scenarios: screening for PEI in patients presenting with symptoms suggestive of Pancreatic Disease, such as abdominal pain or diarrhea; determining the presence of PEI in patients with an established diagnosis of Pancreatic Disease, such as chronic pancreatitis or cystic fibrosis; determining exocrine status in disorders not commonly tested for PEI, but which have a known association with this disorder. Evidence suggests the FE-1 test is reliable for the evaluation of Pancreatic function in many Pancreatic and non-Pancreatic disorders. It is non-invasive, is less time-consuming, and is unaffected by Pancreatic enzyme replacement therapy. Although it cannot be considered the gold-standard method for the functional diagnosis of PEI, the advantages of the FE-1 test make it a very appropriate test for screening patients who may be at risk of this disorder.
-
autoimmune Pancreatic Disease preparation of Pancreatic juice for proteome analysis
Electrophoresis, 2001Co-Authors: Silke Wandschneider, Volker Fehring, Sophia Jacobsemeis, Hansjurgen Thiesen, Matthias LohrAbstract:The identification of Pancreatic proteins is generally hampered by the high content and activity of proteases produced by this organ. The aim of this work was the development of a protocol for the analysis of Pancreatic juice by two-dimensional (2-D) gel electrophoresis allowing consistent and reproducible protein analysis encompassed by high-resolution protein 2-D maps and subtle protein spot recognition without substantial losses due to proteases. Immobilized pH gradient (IPG) strips were used for the first dimension, the second dimension was performed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). However, the key step was the sample preparation technique. Improvements were achieved by using several protease inhibitors (phenylmethylsulfonyl fluoride, aprotinin, L-1 -chloro-3-[4-tosyl-amido]-7-amino-2-heptanine (TLCK)-HCl, Complete) to prevent degradation of the proteins. The application of different pH-ranges was a valuable step for getting an overview of the expressed protein pattern. These investigations resulted in well-resolved 2-D maps with a high reproducibility.
Fred S. Gorelick - One of the best experts on this subject based on the ideXlab platform.
-
precision medicine in Pancreatic Disease knowledge gaps and research opportunities summary of a national institute of diabetes and digestive and kidney Diseases workshop
Pancreas, 2019Co-Authors: Mark E Lowe, Fred S. Gorelick, Dana K Andersen, Richard M Caprioli, Jyoti S Choudhary, Zobeida Cruzmonserrate, Anil K Dasyam, Christopher E Forsmark, Joe W GrayAbstract:A workshop on research gaps and opportunities for Precision Medicine in Pancreatic Disease was sponsored by the National Institute of Diabetes and Digestive Kidney Diseases on July 24, 2019, in Pittsburgh. The workshop included an overview lecture on precision medicine in cancer and 4 sessions: (1) general considerations for the application of bioinformatics and artificial intelligence; (2) omics, the combination of risk factors and biomarkers; (3) precision imaging; and (4) gaps, barriers, and needs to move from precision to personalized medicine for Pancreatic Disease. Current precision medicine approaches and tools were reviewed, and participants identified knowledge gaps and research needs that hinder bringing precision medicine to Pancreatic Diseases. Most critical were (a) multicenter efforts to collect large-scale patient data sets from multiple data streams in the context of environmental and social factors; (b) new information systems that can collect, annotate, and quantify data to inform Disease mechanisms; (c) novel prospective clinical trial designs to test and improve therapies; and (d) a framework for measuring and assessing the value of proposed approaches to the health care system. With these advances, precision medicine can identify patients early in the course of their Pancreatic Disease and prevent progression to chronic or fatal illness.
-
animal models challenges and opportunities to determine optimal experimental models of pancreatitis and Pancreatic cancer
Pancreas, 2019Co-Authors: Jami L. Saloman, Kathryn M. Albers, Brian M. Davis, Mouad Edderkaoui, Guido Eibl, Ariel Y Epouhe, Jeremy Y Gedeon, Fred S. Gorelick, Zobeida Cruzmonserrate, Paul J GrippoAbstract:AbstractAt the 2018 PancreasFest meeting, experts participating in basic research met to discuss the plethora of available animal models for studying exocrine Pancreatic Disease. In particular, the discussion focused on the challenges currently facing the field and potential solutions. That meeting
-
Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer
Pancreas, 2019Co-Authors: Jami L. Saloman, Kathryn M. Albers, Zobeida Cruz-monserrate, Brian M. Davis, Mouad Edderkaoui, Guido Eibl, Ariel Y Epouhe, Jeremy Y Gedeon, Fred S. Gorelick, Paul J GrippoAbstract:At the 2018 PancreasFest meeting, experts participating in basic research met to discuss the plethora of available animal models for studying exocrine Pancreatic Disease. In particular, the discussion focused on the challenges currently facing the field and potential solutions. That meeting culminated in this review, which describes the advantages and limitations of both common and infrequently used models of exocrine Pancreatic Disease, namely, pancreatitis and exocrine Pancreatic cancer. The objective is to provide a comprehensive description of the available models but also to provide investigators with guidance in the application of these models to investigate both environmental and genetic contributions to exocrine Pancreatic Disease. The content covers both nongenic and genetically engineered models across multiple species (large and small). Recommendations for choosing the appropriate model as well as how to conduct and present results are provided.
Jami L. Saloman - One of the best experts on this subject based on the ideXlab platform.
-
animal models challenges and opportunities to determine optimal experimental models of pancreatitis and Pancreatic cancer
Pancreas, 2019Co-Authors: Jami L. Saloman, Kathryn M. Albers, Brian M. Davis, Mouad Edderkaoui, Guido Eibl, Ariel Y Epouhe, Jeremy Y Gedeon, Fred S. Gorelick, Zobeida Cruzmonserrate, Paul J GrippoAbstract:AbstractAt the 2018 PancreasFest meeting, experts participating in basic research met to discuss the plethora of available animal models for studying exocrine Pancreatic Disease. In particular, the discussion focused on the challenges currently facing the field and potential solutions. That meeting
-
Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer
Pancreas, 2019Co-Authors: Jami L. Saloman, Kathryn M. Albers, Zobeida Cruz-monserrate, Brian M. Davis, Mouad Edderkaoui, Guido Eibl, Ariel Y Epouhe, Jeremy Y Gedeon, Fred S. Gorelick, Paul J GrippoAbstract:At the 2018 PancreasFest meeting, experts participating in basic research met to discuss the plethora of available animal models for studying exocrine Pancreatic Disease. In particular, the discussion focused on the challenges currently facing the field and potential solutions. That meeting culminated in this review, which describes the advantages and limitations of both common and infrequently used models of exocrine Pancreatic Disease, namely, pancreatitis and exocrine Pancreatic cancer. The objective is to provide a comprehensive description of the available models but also to provide investigators with guidance in the application of these models to investigate both environmental and genetic contributions to exocrine Pancreatic Disease. The content covers both nongenic and genetically engineered models across multiple species (large and small). Recommendations for choosing the appropriate model as well as how to conduct and present results are provided.
Michael Goggins - One of the best experts on this subject based on the ideXlab platform.
-
the gut microbiome in Pancreatic Disease
Clinical Gastroenterology and Hepatology, 2019Co-Authors: Venkata S Akshintala, Rupjyoti Talukdar, Vikesh K Singh, Michael GogginsAbstract:The gut microbiome increasingly is recognized for its role in human health and Disease. Initial evidence has indicated that gut microbial dysbiosis is associated with several Pancreatic Diseases. Although it is not known if these associations are causative, gut dysbiosis is hypothesized to mediate chronic proinflammatory changes in the pancreas. Further mechanistic and epidemiologic studies of the microbiome are needed. Ultimately, targeted modulation of the microbiota could have therapeutic value.
-
detecting low abundance p16 and p53 mutations in Pancreatic juice using a novel assay heteroduplex analysis of limiting dilution pcrs
Cancer Biology & Therapy, 2006Co-Authors: Yansong Bian, Marcia I. Canto, Hiroyuki Matsubayashi, Tadayoshi Abe, Kathleen M Murphy, Michael GogginsAbstract:We have developed a simple, robust, and highly-sensitive assay for identifying gene mutations in clinical samples. We applied this assay to detect p53 and p16 mutations in Pancreatic juice obtained from patients undergoing evaluation and treatment of Pancreatic Disease. The assay strategy involves PCR amplifying DNA at limiting dilution (LDPCR) followed by screening PCR products for mutations using temperature gradient capillary electrophoresis (TGCE). Compared to conventional TGCE, TGCE after LDPCR significantly increased the number of detectable mutations in Pancreatic duct juice. Using LD-PCR, mutations in p53 and/or p16 were found in the Pancreatic juice of 12 of 20 individuals with Pancreatic cancer compared to only 1 of 8 patients with chronic pancreatitis, and 0 of 8 individuals without evidence of Pancreatic Disease (p
-
dna methylation alterations in the Pancreatic juice of patients with suspected Pancreatic Disease
Cancer Research, 2006Co-Authors: Hiroyuki Matsubayashi, Marcia I. Canto, Norihiro Sato, Alison P Klein, Tadayoshi Abe, Keishi Yamashita, Charles J Yeo, Anthony N Kalloo, Ralph H Hruban, Michael GogginsAbstract:Molecular markers of Pancreatic neoplasia could aid in the evaluation of visible Pancreatic lesions and indicate neoplasia invisible to imaging. We evaluated methylation-specific PCR (MSP) assays that detect aberrantly methylated DNA for their use as markers of Pancreatic neoplasia. Methylation analysis was done on Pancreatic juice collected endoscopically or surgically from 155 individuals with suspected Pancreatic Disease: 56 patients had Pancreatic ductal adenocarcinoma, 17 had intraductal papillary mucinous neoplasms, 26 had symptomatic chronic pancreatitis, 12 controls lacked evidence of Pancreatic Disease, and 44 were asymptomatic individuals at increased risk of developing familial Pancreatic cancer undergoing screening for Pancreatic neoplasia. Pancreatic juice DNA was analyzed for promoter methylation using conventional MSP assays for 17 genes. For six genes, Pancreatic juice methylation was quantified using real-time quantitative MSP (QMSP; Cyclin D2, FOXE1, NPTX2, ppENK, p16, and TFPI2). Quantifying Pancreatic juice methylation using QMSP with a cutoff of >1% methylated DNA could better predict Pancreatic cancer than detecting methylation using conventional MSP. In the endoscopic group, 9 of 11 patients with Pancreatic cancer, but none of 64 individuals without neoplasia had > or =1% methylation for two or more of the best five QMSP assays (82% sensitivity and 100% specificity; P < 0.0001). The prevalence of Pancreatic juice methylation in patients with chronic pancreatitis was less than in patients with Pancreatic cancer but higher than in controls and similar to high-risk individuals. The detection and quantification of aberrantly methylated DNA in Pancreatic juice is a promising approach to the diagnosis of Pancreatic cancer.
